🚨 In our new paper led by @[email protected] in collaboration w/ Prof. Joe Loscalzo harvardmed.bsky.social, just published in @[email protected], we outline why the next generation #NetworkMedicine 2.0 must move beyond isolated system components to embrace true biological #complexity 2/

Harvard Medical School (@harva...
Harvard Medical School (@harvardmed.bsky.social)

Bluesky Social

šŸ“£ New Article from Network and Systems Medicine on #ScienceOpen!

šŸ†•šŸ“„ 'Identification of Transcriptional Regulators Using a Combined Disease Module Identification and Prize-Collecting Steiner Tree Approach' āž”ļø https://drugrepocentral.scienceopen.com/hosted-document?doi=10.14293/NSM.25.1.0003

#REPO4EU #NetworkMedicine #Bioinformatics #TranscriptionFactors

Identification of Transcriptional Regulators Using a Combined Disease Module Identification and Prize-Collecting Steiner Tree Approach

<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d4991e168">Transcription factors play important roles in maintaining normal biological function, and their dysregulation can lead to the development of diseases. Identifying candidate transcription factors involved in disease pathogenesis is thus an important task for deriving mechanistic insights from gene expression data. We developed Transcriptional Regulator Identification using Prize-collecting Steiner trees (TRIPS), a workflow for identifying candidate transcriptional regulators from case–control expression data. In the first step, TRIPS combines the results of differential expression analysis with a disease module identification step to retrieve perturbed subnetworks comprising an expanded gene list. TRIPS then solves a prize-collecting Steiner tree problem on a gene regulatory network, thereby identifying candidate transcriptional modules and transcription factors. We compare TRIPS to relevant methods using publicly available disease datasets and show that the proposed workflow can recover known disease-associated transcription factors with high precision. Network perturbation analyses demonstrate the reliability of TRIPS results. We further evaluate TRIPS on Alzheimer’s disease, diabetic kidney disease, and prostate cancer single-cell omics datasets. Overall, TRIPS is a useful approach for prioritizing transcriptional mechanisms for further downstream analyses. </p>

ScienceOpen

'Enhancing the Accuracy of Network Medicine Through Understanding the Impact of Sample Size in Gene Co-expression Networks' - a Network and Systems Medicine published article on #ScienceOpen šŸ“„šŸ”“

āž”ļø https://drugrepocentral.scienceopen.com/hosted-document?doi=10.14293/NSM.25.1.0002

#REPO4EU #NetworkMedicine #SampleSizeMatters #GeneCoexpression #OpenAccess

Enhancing the Accuracy of Network Medicine Through Understanding the Impact of Sample Size in Gene Co-expression Networks

<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d3821688e235">Network medicine relies on RNA sequencing to infer gene co-expression networks, which are crucial to identify functional gene clusters and gene regulatory interactions, and offer a deeper understanding of disease phenotypes and drug mechanisms. It remains unknown, however, how many samples do we need to make reliable predictions. Here, we propose a power-law model to predict the relationship between the number of inferred significant interactions and sample size, allowing us to quantitatively link sample size to the accuracy of the inferred networks. We apply our model to investigate the effect of sample size on biomarker discovery and differentiation of protein–protein interactions from non-interacting pairs, ultimately unveiling the critical role of data quality in generating meaningful predictions in network medicine. </p>

ScienceOpen

šŸ”šŸ“„ 'Prioritizing repurposable drugs for Alzheimer's disease using network-based analysis with concurrent assessment of Long QT syndrome risk.' - a #DrugRepurposing Research article on #ScienceOpen:

āž”ļø https://www.scienceopen.com/document?vid=c8f12215-0b3a-413c-bac7-ed5d27981865

#REPO4EU #NetworkMedicine #AlzheimersResearch #QTInterval #Interactome #Bioinformatics

Prioritizing repurposable drugs for Alzheimer’s disease using network-based analysis with concurrent assessment of Long QT syndrome risk

<p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d3176694e169"> <div class="list"> <a class="named-anchor" id="celist0001"> <!-- named anchor --> </a> <ul class="so-custom-list" style="list-style-type: none"> <li id="celistitem0001"> <div class="so-custom-list-label so-ol">•</div> <div class="so-custom-list-content so-ol"> <p dir="auto" id="para0001">Identification of repurposable drugs for AD.</p> </div> </li> <li id="celistitem0002"> <div class="so-custom-list-label so-ol">•</div> <div class="so-custom-list-content so-ol"> <p dir="auto" id="para0002">Filtering of drugs at risk for LQTS using diffusion- and modularity-based methods.</p> </div> </li> <li id="celistitem0003"> <div class="so-custom-list-label so-ol">•</div> <div class="so-custom-list-content so-ol"> <p dir="auto" id="para0003"> <i>In-silico</i>-validation of candidate compounds for AD mitigation through GSEA analysis. </p> </div> </li> <li id="celistitem0004"> <div class="so-custom-list-label so-ol">•</div> <div class="so-custom-list-content so-ol"> <p dir="auto" id="para0004">Promising compounds include acamprosate, tolcapone, sitagliptin, and diazoxide.</p> </div> </li> </ul> </div> </p><p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d3176694e194">Alzheimer's disease affects 6.9 million Americans aged 65 and older, a number expected to double by 2060. Eight FDA-approved drugs target Alzheimer's, but no cure is available, and most treatments are symptomatic. Drug repurposing, the use of FDA-approved drugs for new indications, is a promising strategy to address this lack of effective therapies. However, despite prior safety approval, repurposable drugs may still trigger unexpected side-effects in new contexts. This study introduces a network-based approach to minimize side-effect risk in drug repositioning, focusing on QT interval prolongation, a cardiac side-effect observed in Alzheimer's patients treated with acetylcholinesterase inhibitors. The method integrates Mode-of-Action and Random Walk with Restart analyses to identify repositioning candidates while assessing QT-related risk. This strategy identified promising compounds including acamprosate, tolcapone, sitagliptin, and diazoxide, with potential to mitigate disease pathology. Gene set enrichment analysis was used to computationally assess the compounds' ability to reverse disease-related gene expression signatures. </p><p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d3176694e199"> <div class="fig panel" id="fig0005"> <a class="named-anchor" id="fig0005"> <!-- named anchor --> </a> <div class="figure-container so-text-align-c"> <img alt="" class="figure" src="/document_file/bf57ab42-eed2-4b4e-b64d-482ee8ce1ce1/PubMedCentral/image/ga1"/> </div> <div class="panel-content"/> </div> </p>

ScienceOpen

'Multimorbidity Patterns in Patients with Pulmonary Arterial Hypertension Identified Through Hospital Discharge Records: A Network-Based Analysis' - an article in Cardiovascular Innovations and Applications on #ScienceOpen:

šŸ”— https://www.scienceopen.com/hosted-document?doi=10.15212/CVIA.2025.0008

šŸ–‡ļø #CardiovascularMedicine #CardiologyResearch #Multimorbidity #NetworkMedicine

Multimorbidity Patterns in Patients with Pulmonary Arterial Hypertension Identified Through Hospital Discharge Records: A Network-Based Analysis

<div xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="section"> <a class="named-anchor" id="d7816681e172"> <!-- named anchor --> </a> <h5 class="section-title" id="d7816681e173">Background:</h5> <p dir="auto" id="d7816681e175">Considerable variability exists in the clinical presentations of pulmonary arterial hypertension (PAH). Greater understanding of the comorbidities observed in Chinese patients with PAH is urgently needed. </p> </div><div xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="section"> <a class="named-anchor" id="d7816681e177"> <!-- named anchor --> </a> <h5 class="section-title" id="d7816681e178">Methods:</h5> <p dir="auto" id="d7816681e180">This 10-year retrospective analysis was based on clinical data from hospital discharge records for individuals diagnosed with PAH (n = 2584). We used propensity score matching to match patients with PAH to individuals without a PAH diagnosis in a ratio of 1:1, by age, sex, discharge time, and department, over the same period. We constructed multimorbidity networks based on sex and age, and used the cosine index to measure the co-occurrence of chronic diseases. </p> </div><div xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="section"> <a class="named-anchor" id="d7816681e182"> <!-- named anchor --> </a> <h5 class="section-title" id="d7816681e183">Results:</h5> <p dir="auto" id="d7816681e185">The mean numbers of comorbidities were 4.7 and 3.8 for patients with PAH and controls, respectively. The main central and hub disorders were renal osteodystrophy, cardiovascular illnesses, background retinopathy, diabetes mellitus, systemic lupus erythematosus, epilepsy, and autoimmune hemolytic anemia. The average neighbor degree and closeness were significantly smaller in the multimorbidity networks of patients with PAH than control participants (Kolmogorov–Smirnov test, all P < 0.05). </p> </div><div xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="section"> <a class="named-anchor" id="d7816681e187"> <!-- named anchor --> </a> <h5 class="section-title" id="d7816681e188">Conclusion:</h5> <p dir="auto" id="d7816681e190">Our findings may aid in preventing comorbidities among patients with PAH and deepening understanding of the underlying physiopathological mechanisms. </p> </div>

ScienceOpen

🧬Too many cancer drug combinations, too little time — can AI help us find the winners and avoid the risky ones?

šŸ”— Network-based estimation of therapeutic efficacy and adverse reaction potential for prioritisation of anti-cancer drug combinations. Computational and Structural Biotechnology Journal, DOI: https://doi.org/10.1016/j.csbj.2024.12.003

šŸ“š CSBJ: https://www.csbj.org/

#CancerTherapy #DrugDiscovery #NetworkMedicine #Bioinformatics #PrecisionOncology #SystemsPharmacology #AIinHealthcare

Very happy for the invitation to present our MyAura project (summary paper below) to the #ClinicalInformationSystems Working Group at the American Medical Informatics Association (@amiainformatics.bsky.social ), Friday, April 4, noon EST. #BiomedicalInformatics #NetworkMedicine #KnowledgeGraphs #NetworkScience
https://academic.oup.com/jamia/advance-article/doi/10.1093/jamia/ocaf012/7994402

So happy this NLM-NIH sponsored work with @alfonsovalencia , @jonsv89, Rion Correia et al is out @BMCMedicine!

We study #DrugInteraction #polypharmacy with longitudinal #DataScience and #NetworkMedicine study of #EHR revealing #gender #age #bias in #health.

https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-024-03384-1

Prevalence and differences in the co-administration of drugs known to interact: an analysis of three distinct and large populations - BMC Medicine

Background The co-administration of drugs known to interact greatly impacts morbidity, mortality, and health economics. This study aims to examine the drug–drug interaction (DDI) phenomenon with a large-scale longitudinal analysis of age and gender differences found in drug administration data from three distinct healthcare systems. Methods This study analyzes drug administrations from population-wide electronic health records in Blumenau (Brazil; 133 K individuals), Catalonia (Spain; 5.5 M individuals), and Indianapolis (USA; 264 K individuals). The stratified prevalences of DDI for multiple severity levels per patient gender and age at the time of administration are computed, and null models are used to estimate the expected impact of polypharmacy on DDI prevalence. Finally, to study actionable strategies to reduce DDI prevalence, alternative polypharmacy regimens using drugs with fewer known interactions are simulated. Results A large prevalence of co-administration of drugs known to interact is found in all populations, affecting 12.51%, 12.12%, and 10.06% of individuals in Blumenau, Indianapolis, and Catalonia, respectively. Despite very different healthcare systems and drug availability, the increasing prevalence of DDI as patients age is very similar across all three populations and is not explained solely by higher co-administration rates in the elderly. In general, the prevalence of DDI is significantly higher in women — with the exception of men over 50 years old in Indianapolis. Finally, we show that using proton pump inhibitor alternatives to omeprazole (the drug involved in more co-administrations in Catalonia and Blumenau), the proportion of patients that are administered known DDI can be reduced by up to 21% in both Blumenau and Catalonia and 2% in Indianapolis. Conclusions DDI administration has a high incidence in society, regardless of geographic, population, and healthcare management differences. Although DDI prevalence increases with age, our analysis points to a complex phenomenon that is much more prevalent than expected, suggesting comorbidities as key drivers of the increase. Furthermore, the gender differences observed in most age groups across populations are concerning in regard to gender equity in healthcare. Finally, our study exemplifies how electronic health records’ analysis can lead to actionable interventions that significantly reduce the administration of known DDI and its associated human and economic costs.

BioMed Central
Life may be less chaotic than we thought, say physicists

According to a long-standing idea, life exists at the edge of chaos, meaning it is sensitive enough to respond to small environmental changes. But an analysis of processes that occur inside cells challenges the idea

New Scientist